Elucidating the Pathogenic Role of Helicobacter pylori Infection in Hematologic Disorders: Mechanistic Insights and Future Perspectives
Eliminating H. pylori restores blood counts in people with associated anemia and clotting disorders, offering targeted disease reversal.
This comprehensive review integrates mechanistic and clinical insights into H. pylori-associated hematologic manifestations including IDA, B12 deficiency, ITP, and MALT lymphoma, highlighting eradication therapy as a clinically effective intervention that restores hematologic parameters through targeted pathogen removal. The review identifies gaps in diagnostic precision and variability in patient response that warrant individualized management strategies.
What the study was
- Study design
- Narrative review
- Population
- Patients with H. pylori-associated hematologic disorders (IDA, B12 deficiency, ITP, MALT lymphoma); general human population (H. pylori prevalence ~44% globally)
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Helicobacter
Why it surfaced
Solid review of a clinically relevant topic (H. pylori in hematology). Value primarily as reference synthesis; lower novelty given established literature.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.